Results 81 to 90 of about 2,191 (109)

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. [PDF]

Front Cell Infect Microbiol, 2022
Barroso DH, Gonçalves RT, Barbosa JS, da Motta JOC, Freire GSM, Gomes CM, Sampaio RNR.   +6 more
europepmc   +1 more source

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial. [PDF]

PLoS Negl Trop Dis, 2022
Javadi A, Khamesipour A, Ghoorchi M, Bahrami M, Khatami A, Sharifi I, Eskandari SE, Fekri A, Aflatoonian MR, Firooz A.   +9 more
europepmc   +1 more source

Changes in serological, inflammatory, and serum protein electrophoretic markers during ongoing meglumine antimoniate plus allopurinol therapy in canine leishmaniosis. [PDF]

Vet Res Commun
Giner J, González A, Lebrero ME, Quilez P, Guallar D, Gómez Á, Marteles-Aragüés D, Villanueva-Saz S.   +7 more
europepmc   +1 more source

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate. [PDF]

Bioanalysis, 2021
Garay-Baquero DJ, Rebellón-Sánchez DE, Prieto MD, Giraldo-Parra L, Navas A, Atkinson S, McDougall S, Gómez MA.   +7 more
europepmc   +1 more source

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime^®) in Cutaneous Leishmaniasis. [PDF]

Nanomaterials (Basel), 2021
Albalawi AE, Abdel-Shafy S, Khudair Khalaf A, Alanazi AD, Baharvand P, Ebrahimi K, Mahmoudvand H.   +6 more
europepmc   +1 more source

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil. [PDF]

PLoS Negl Trop Dis, 2021
Oliveira-Ribeiro C, Pimentel MIF, Oliveira LFA, Vasconcellos ÉCFE, Conceição-Silva F, Schubach AO, Fagundes A, de Mello CX, Mouta-Confort E, Miranda LFC, Valete-Rosalino CM, Martins ACDC, Oliveira RVC, Quintella LP, Lyra MR.   +14 more
europepmc   +1 more source

Response and therapeutic failure to meglumine antimoniate, the first-line drug for cutaneous leishmaniasis infections in Colombian soldiers. [PDF]

Parasitol Res
Pavia PX, Patiño LH, Méndez C, Romero Y, Duque MC, Cruz C, Ramírez JD.   +6 more
europepmc   +1 more source

Topical Meglumine Antimoniate Gel for Cutaneous Leishmaniasis: Formulation, Evaluation, and In Silico Insights. [PDF]

Gels
Sosa L, Espinoza LC, Pujol A, Correa-Basurto J, Méndez-Luna D, Sarango-Granda P, Berenguer D, Riera C, Clares-Naveros B, Calpena AC, Prohens R, Silva-Abreu M.   +11 more
europepmc   +1 more source

Correction: Successful treatment of meglumine antimoniate in patient with cutaneous leishmaniasis with end-stage renal failure undergoing hemodialysis: a case report. [PDF]

J Med Case Rep
Arab H, Alsaffaf Y, Aldolly A, Dukhan A, Douri T.   +4 more
europepmc   +1 more source

Efficacy of meglumine antimoniate treatment on boxer <i>Leishmania infantum</i> skin lesions: case report. [PDF]

Front Vet Sci
Carresi C, Ferrucci CF, Mangano C, Coppoletta AR, Cardamone A, Musolino V, Gliozzi M, Mollace V, Britti D.   +8 more
europepmc   +1 more source